Introduction
Attention-deficit/hyperactivity disorder (ADHD) is one of the most commonly diagnosed and treated childhood psychiatric disorders. Children are hyperactive (fidgety and unable to sit still for long periods), and impulsive (doing things without stopping to think). They find it hard to concentrate and follow instructions, and to regulate their emotions. This results in problems at school, at home, and with their peers where they struggle to fit in,1 and get into trouble.2 Heterogeneity (non-uniformity) is a feature of ADHD expression. Children often have a wide range of other diagnoses and co-occurring problems such as autism spectrum conditions (ASCs) (50%–75%),3 conduct disorders (24%),4 sleep disorders (25%–50%),5 tics (60%),6 gut dysbiosis,7 obesity (40%),8 anxiety, depression (33%),9 reading and other learning problems.10
Treating ADHD is challenging. Interventions are offered to help manage symptoms. The National Health Service (NHS) offers National Institute for Health and Care Excellence (NICE) recommended treatments of behaviour change programmes and pharmaceutical medications. Recent NICE updates suggest also asking about diet and offering advice if relevant. While implemented, recommended treatments often palliate some symptoms making classroom and family life more manageable, however, their long-term effectiveness and ability to address important negative outcomes remains in doubt.11 Adherence is poor and side effects of pharmaceutical medications common.12
While the majority of carers of children with ADHD in the UK rely on NICE recommended treatments, a number try other treatments, identified by themselves rather than doctor recommendation, and usually requiring out of pocket payments. Such treatments are collectively described in a variety of ways, and their categorisation also varies.
For the purposes of this article such treatments will be referred to as ‘non-mainstream’. Other descriptive terms for non-mainstream are ‘complementary and/or complementary medicine’ referring to a broad set of healthcare practices that are not part of that country’s own tradition or conventional medicine and not fully integrated into the dominant healthcare system.13 The term ‘integrative’ is used when conventional and complementary approaches are used in a coordinated way (https://nccih.nih.gov). Treatments move from non-mainstream to mainstream as their evidence base and/or acceptability grows.
Non-mainstream treatments are also described as ‘natural’.14 Although doctors can be uncomfortable recommending treatments about which they are unknowledgeable and untrained,15 there is a growing interest in using natural medicines particularly in paediatrics.16 17
Carer use of non-mainstream treatments for ADHD has been found to be driven by a desire for alternatives to pharmaceutical medications,17–19; to minimise symptoms of ADHD; for additional benefit combined with conventional treatment; to avoid prescribed medication side effects,20 21 and dissatisfaction with conventional care.22 Ninety per cent+ carers of children with ADHD surveyed hope to see more research on non-mainstream treatments conducted.23
Surveys in several countries have sought to identify which and how frequently non-mainstream treatments are used to manage ADHD. Using Google Scholar, Web of Science and cross-referencing, 10 such surveys were found: three in Australia, five in the USA, one in Canada and one in Israel (table 1). No surveys were identified in the UK. This survey seeks to address this gap. Data about resource use was collected from a convenience sample of families recruited to the Sheffield Treatments for ADHD Research (STAR) project. The project used Trials within Cohorts (TwiCs) methodology,24 whereby first a large observational cohort of participants with the condition of interest was recruited and their outcomes of interest regularly measured.
This report describes the resource use reported by cohort participants at entry into the observational cohort (online supplemental appendix 1).25 Results of the pilot randomised controlled trials (RCTs) conducted within the cohort and detailed population characteristics are reported elsewhere.26
Patient and public involvement
The STAR project was preceded by a case series.27 Families with children with ADHD participating in this preceding study expressed frustration at the lack of helpful treatment options and a desire to support research testing new treatments which might help their children. These families contributed to the design of the STAR project including: the design and piloting of the study questionnaire where an extra open-ended question ‘use this space for anything else you would like to tell us’ was added (see online supplemental appendix 1); and the generation of an interactive hip-hop rap performance called Lost Voices based on participating family’s stories, which was widely shared on Facebook and helped increase recruitment.28